ROS implication in a new antitumor strategy based on non‐thermal plasma

TLDR

Non‑thermal plasma generates reactive species at ambient temperature and is a promising, non‑thermal approach for treating diseases such as cancer. The study aimed to assess the antitumor potential of NTP in vitro and in vivo. The authors tested NTP on glioblastoma U87MG and colorectal carcinoma HCT‑116 cell lines to evaluate its antitumor activity. NTP produced ROS that caused DNA damage, cell‑cycle arrest, and apoptosis, and in U87MG‑bearing mice it reduced tumor bioluminescence and volume, confirming its therapeutic promise.

Abstract

Abstract Non‐thermal plasma (NTP) is generated by ionizing neutral gas molecules/atoms leading to a highly reactive gas at ambient temperature containing excited molecules, reactive species and generating transient electric fields. Given its potential to interact with tissue or cells without a significant temperature increase, NTP appears as a promising approach for the treatment of various diseases including cancer. The aim of our study was to evaluate the interest of NTP both in vitro and in vivo. To this end, we evaluated the antitumor activity of NTP in vitro on two human cancer cell lines (glioblastoma U87MG and colorectal carcinoma HCT‐116). Our data showed that NTP generated a large amount of reactive oxygen species (ROS), leading to the formation of DNA damages. This resulted in a multiphase cell cycle arrest and a subsequent apoptosis induction. In addition, in vivo experiments on U87MG bearing mice showed that NTP induced a reduction of bioluminescence and tumor volume as compared to nontreated mice. An induction of apoptosis was also observed together with an accumulation of cells in S phase of the cell cycle suggesting an arrest of tumor proliferation. In conclusion, we demonstrated here that the potential of NTP to generate ROS renders this strategy particularly promising in the context of tumor treatment.